Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Citi
McKinsey
Mallinckrodt
Harvard Business School
Chubb

Generated: May 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,101,569

« Back to Dashboard

Which drugs does patent 7,101,569 protect, and when does it expire?

Patent 7,101,569 protects LEVOXYL and is included in one NDA.

This patent has twenty-six patent family members in nine countries.

Summary for Patent: 7,101,569
Title:Methods of administering levothyroxine pharmaceutical compositions
Abstract:The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.
Inventor(s): Franz; G. Andrew (St. Louis, MO), Strauss; Elaine A. (Seminole, FL), DiMenna; Phillip A. (St. Petersburg, FL), Gemma; Rocco L. (Dover, OH)
Assignee:
Application Number:10/218,718
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,101,569
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 7,101,569

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-001 May 25, 2001 AB1,AB3 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF USE OF ADMINISTERING LEVOTHYROXINE ➤ Try a Free Trial
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-002 May 25, 2001 AB1,AB3 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF USE OF ADMINISTERING LEVOTHYROXINE ➤ Try a Free Trial
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-003 May 25, 2001 AB1,AB3 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF USE OF ADMINISTERING LEVOTHYROXINE ➤ Try a Free Trial
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-004 May 25, 2001 AB1,AB3 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF USE OF ADMINISTERING LEVOTHYROXINE ➤ Try a Free Trial
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-005 May 25, 2001 AB1,AB3 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF USE OF ADMINISTERING LEVOTHYROXINE ➤ Try a Free Trial
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-006 May 25, 2001 AB1,AB3 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF USE OF ADMINISTERING LEVOTHYROXINE ➤ Try a Free Trial
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-007 May 25, 2001 AB1,AB3 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF USE OF ADMINISTERING LEVOTHYROXINE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,101,569

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002240394 ➤ Try a Free Trial
Australia 2002258397 ➤ Try a Free Trial
Australia 2002332507 ➤ Try a Free Trial
Australia 2002341555 ➤ Try a Free Trial
Australia 2002362468 ➤ Try a Free Trial
Brazil 0207297 ➤ Try a Free Trial
Brazil 0207299 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Deloitte
Mallinckrodt
Medtronic
Covington
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.